The long awaited divestment of ANH disappointed on deal value (EV € 2.2bn, including a potential earn-out of up to € 0.5bn), but creates a group with a much more comprehensive activity and earnings profile. We still appreciate dsm-firmenich for its broad portfolio and market leading positions in consumer-oriented businesses in Nutrition, Health and Beauty. We remind that we have already lowered our target price upon the ANH divestment announcement last week so we maintain our current € 82 target...
Home Invest reports results in line with our expectations at €1,21 EPRA EPS. It guides €1,23 EPRA EPS in FY26, slightly ahead of our expectation of € 1,20. At 1H25 results, Home Invest confirmed our thesis that the building right in Louvain-La-Neuve will not get renewed. As of the announcement Home Invest started to underperform (-7,1%) the EPRA index (+8,6%). The UCL has time until June 2026 to respond. This headwind will keep EPRA EPS growth muted, despite the stellar operational results: 98,...
Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...
4Q adj EBITDA for the continuing operations dropped by 4% y/y and was about 4% below our forecast and 3% below consensus. Dsm-firmenich's did not give FY26 guidance at this stage but promised to do so in the upcoming Investor Event (12 March). We remind that the long awaited and recently announced divestment of ANH disappointed on deal value (EV € 2.2bn, including a potential earn-out of up to € 0.5bn), but creates a group with a much more comprehensive activity and earnings profile. We still ap...
dsm-firmenich reports full year 2025 results Press ReleaseKaiseraugst (Switzerland), Maastricht (Netherlands), February 12, 2026 dsm-firmenich reports full year 2025 results Management Report 2025 highlights Good financial performance, with strong contribution from synergiesStrategic plan now fully executed following the announced divestment of Animal Nutrition & HealthAnimal Nutrition & Health has been classified as Assets Held for Sale and Discontinued OperationsNew €500 million share repurchase program to be launched in Q1 2026Maintain stable dividend of €2.50 per share, adopting st...
RESULTATS ANNUELS 2025 INFORMATION RÉGLEMENTÉEBruxelles, 11 février 2026, 17h55 DES RÉSULTATS 2025 SOLIDES CONFIRMANT LA STRATÉGIE DE NEXTENSA Nextensa a clôturé l’exercice financier 2025 avec des résultats solides, confirmant une nette amélioration de sa rentabilité (+€ 33,8 M), portée par une contribution accrue des activités de développement (+€ 1,8 M), la baisse des coûts de financement (-€ 9,2 M) et la poursuite du renforcement du bilan. Au cours des exercices 2024 et 2025, Nextensa a réalisé plusieurs transactions ciblées pour un montant total de € 360 M. Grâce à cette approch...
JAARRESULTATEN 2025 GEREGLEMENTEERDE INFORMATIEBrussel, 11 februari 2026, 17u55 STERKE RESULTATEN OVER 2025 BEVESTIGEN DE STRATEGIE VAN NEXTENSA Nextensa sloot het boekjaar 2025 af met sterke resultaten, waarmee een duidelijke stijging van de winstgevendheid werd bevestigd (+€ 33,8 M), gedreven door een hogere bijdrage van de ontwikkelingsactiviteiten (+€ 1,8 M), lagere financieringskosten (-€ 9,2 M) en een verdere versterking van de balans. In 2024 en 2025 realiseerde Nextensa meerdere gerichte transacties voor een totaalbedrag van € 360 M. Als rechtstreeks gevolg van deze gediscipl...
ANNUAL RESULTS 2025 REGULATED INFORMATIONBrussels, 11 February 2026, 5:55 PM STRONG FULL-YEAR 2025 RESULTS CONFIRM NEXTENSA’S STRATEGIC COURSE Nextensa closed the 2025 financial year with strong results, confirming a clear increase in profitability (+€33.8 M) driven by a higher contribution from development activities (+1.8 M), lower financing costs (-9.2 M) and a continued balance sheet strengthening. During 2024 and 2025, Nextensa executed several targeted transactions for a total amount of €360 M. As a direct outcome of this disciplined capital recycling approach, Nextensa reduced...
dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH) Press Release dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH) Kaiseraugst (Switzerland), Maastricht (Netherlands), February 9, 2026 Following the announced divestment of Animal Nutrition & Health (ANH) activities to CVC Capital Partners, the assets and liabilities of the divested business have been classified as Assets Held for Sale, and the financial results of the ANH activities have bee...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.